MARLBOROUGH, Mass.,
Sept. 17, 2018 /PRNewswire/ -- Boston
Scientific Corporation (NYSE: BSX) today announced key data that
will be presented at the 30th Transcatheter Cardiovascular
Therapeutics (TCT), the annual scientific symposium of the
Cardiovascular Research Foundation, in San Diego, on September
21 - September 25.
Data from the head-to-head IMPERIAL trial evaluating the ELUVIA™
Drug-Eluting Vascular Stent System and the Zilver® PTX® Stent for
treatment of superficial femoral or proximal popliteal lesions will
be featured during a late-breaking clinical trial session on
Saturday, September 22. Two-year
outcomes data from the REPRISE III study, a head-to-head comparison
of the LOTUS™ Aortic Valve System to the CoreValve™ Evolut™ R in
high-risk patients with severe aortic stenosis, will also be
highlighted at the meeting.
"The data being presented at TCT will provide important clinical
evidence to assist physicians to make informed treatment decisions
for the patients they serve," said Professor Ian Meredith, M.D., executive vice president and
global chief medical officer, Boston Scientific. "We look forward
to sharing the findings from the IMPERIAL trial, a
first-of-its-kind large randomized safety and effectiveness trial,
studying the use of drug-eluting stents for peripheral artery
disease. Our investment in these key studies exemplifies our
continued commitment to advancing science in the field of
interventional vascular therapies, and ultimately, improving care
for all patients."
All presentations are listed in Pacific Time and will take place
at the San Diego Convention
Center.
PRESENTATIONS OF INTEREST (listed chronologically)
Friday, September 21
- LOTUS Aortic Valve System: Final 5-Year Outcomes Of The
REPRISE II Study: Long-Term Outcomes With the Fully Repositionable
and Retrievable Lotus Transcatheter Aortic Valve: Nicolas
Dumontiel, M.D., will present at 1:15
p.m. in Room 28D-E, Upper Level.
- LOTUS Aortic Valve System: Two-Year Outcomes After
Transcatheter Aortic Valve Replacement With Mechanically- versus
Self-Expandable Valves: Results From The REPRISE III Randomized
Trial: Michael J. Reardon, M.D.,
will present at 1:30 p.m. in Room
28D-E, Upper Level.
Saturday, September 22
- ELUVIA Drug-Eluting Vascular Stent System: IMPERIAL: A
Randomized Trial of Drug-Eluting Stents for Treatment of
Femoropopliteal Artery Lesions: William A.
Gray, M.D., will present at 10:21
a.m. in the Main Arena, Hall F, Ground Level.
Sunday, September 23
- PROMUS Element™ Plus Everolimus-Eluting Stent System:
Final 5-Year Results in Unselected Patients Implanted With A
Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent: the PROMUS
Element Plus Us Post-Approval Study: David
E. Kandzari, M.D., will present at 11:30 a.m. in the Exhibit Hall, Ground Level, at
Moderated Posters 8.
- LOTUS Aortic Valve System: Paravalvular Leak in the
RESPOND Post-Market Study- Predictors and Impact on 2-Year Clinical
Outcomes Following TAVR With A Fully Repositionable and Retrievable
Aortic Valve in Routine Clinical Practice: Jochen Wöhrle, M.D.,
will present at 2:57 p.m. in the
Exhibit Hall, Ground Level, at Moderated Posters 5.
Monday, September 24
- SYNERGY™ Bioabsorbable Polymer Stent: Baseline
Characteristics and 3-Month Outcomes of the EVOLVE Short DAPT Trial
- A Prospective investigation of Abbreviated Antiplatelet Therapy
in High Bleeding Risk Patients Treated With A Thin-Strut
Bioabsorbable Polymer-Coated, Everolimus-Eluting Stent:
Ajay J. Kirtane, M.D., will present
at 10:30 a.m. in the Exhibit Hall,
Ground Level, at Moderated Posters 6.
For more information, visit
http://www.bostonscientific.com/en-US/medical-specialties/interventional-cardiology/conferences-and-events/tct.html
or during TCT visit the Boston Scientific booth #507.
The company will also host an investor event and webcast on
Monday, September 24 from 9:00 – 10:00
a.m. PT to provide a business update and answer questions
from investors about the Boston Scientific cardiovascular
portfolio. The event will be accessible at
www.bostonscientific.com/investors. A replay of the webcast will be
accessible at www.bostonscientific.com/investors beginning
approximately one hour following the completion of the event.
In the U.S., the ELUVIA Stent System is an investigational
device and is not available for sale.
The LOTUS Valve system is not available for use or sale.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology leader
for more than 35 years, we advance science for life by providing a
broad range of high performance solutions that address unmet
patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like
"anticipate," "expect," "project," "believe," "plan," "estimate,"
"intend" and similar words. These forward-looking statements are
based on our beliefs, assumptions and estimates using information
available to us at the time and are not intended to be guarantees
of future events or performance. These forward-looking statements
include, among other things, statements regarding the acquisition,
the financial and business impact of the transaction, product
launches and product performance and impact. If our underlying
assumptions turn out to be incorrect, or if certain risks or
uncertainties materialize, actual results could vary materially
from the expectations and projections expressed or implied by our
forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could
affect our ability to implement our business strategy and may cause
actual results to differ materially from those contemplated by the
statements expressed in this press release. As a result, readers
are cautioned not to place undue reliance on any of our
forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; the
closing and integration of acquisitions; intellectual property;
litigation; financial market conditions; and future business
decisions made by us and our competitors. All of these factors are
difficult or impossible to predict accurately and many of them are
beyond our control. For a further list and description of these and
other important risks and uncertainties that may affect our future
operations, see Part I, Item 1A – Risk Factors in our most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A – Risk Factors
in Quarterly Reports on Form 10-Q we have filed or will file
hereafter. We disclaim any intention or obligation to publicly
update or revise any forward-looking statements to reflect any
change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.
CONTACT:
Timette Nevala
Manager, Communications
(763) 494-1284 (office)
Timette.Nevala@bsci.com
Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
(508) 683-5565 (office)
BSXInvestorRelations@bsci.com
View original
content:http://www.prnewswire.com/news-releases/boston-scientific-announces-scheduled-presentations-at-transcatheter-cardiovascular-therapeutics-2018-300713917.html
SOURCE Boston Scientific Corporation